BMY Q1 2020 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q1 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$10.8B+82.1% YoY

Gross Profit

$4.8B45.0% margin

Operating Income

$928M8.6% margin

Net Income

-$775M-7.2% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+35.7%

Cash Flow

Operating Cash Flow

$3.9B

Free Cash Flow

$3.8B

Stock-Based Comp.

$210M

Balance Sheet

Total Assets

$129.3B

Total Liabilities

$79.3B

Stockholders' Equity

$49.9B

Cash & Equivalents

$15.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10.8B	$5.9B	+82.1%
Gross Profit	$4.8B	$4.1B	+18.6%
Operating Income	$928M	$1.8B	-48.0%
Net Income	-$775M	$1.7B	-145.3%

Revenue Segments

Revlimid

$2.9B27%

Eliquis

$2.6B25%

Opdivo

$1.8B17%

Orencia

$714M7%

Pomalyst/Imnovid

$713M7%

Sprycel

$521M5%

Mature Products And All Other

$418M4%

Yervoy

$396M4%

Abraxane

$300M3%

Baraclude

$122M1%

Empliciti

$97M1%

Reblozyl

$8M0%

Geographic Segments

UNITED STATES

$6.8B63%

Europe

$2.6B24%

Rest Of World

$1.3B12%

Other Region

$113M1%